Development of neurocognitive disorders in HIV/AIDS

Neurobehavioral HIV Medicine

Volumn 3, Issue 1, 2011, Pages 9-18

  Dennis, Brandon C ^a,b   Houff, Sidney A ^a   Han, Dong Y ^a   Schmitt, Frederick A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

AIDS; AIDS dementia; HIV dementia; HIV associated neurocognitive disorders

Indexed keywords

ANTIRETROVIRUS AGENT; MEMANTINE; N ACETYLASPARTIC ACID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ALZHEIMER DISEASE; ANXIETY DISORDER; APHASIA; ATTENTION; BLOOD BRAIN BARRIER; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; COMPARATIVE STUDY; DEPRESSION; DEPTH PERCEPTION; DISEASE CLASSIFICATION; DISEASE COURSE; EDUCATION; HEART INFARCTION; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTELLIGENCE; MEMORY DISORDER; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PSYCHOMOTOR DISORDER; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; SURVIVAL; WORKING MEMORY;

EID: 81355163042     PISSN: None     EISSN: 11791497     Source Type: Journal    
DOI: 10.2147/NBHIV.S7170     Document Type: Review

References (108)

1. Centers for Disease Control and Prevention. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb Mortal Wkly Rep. 1981;30(25): 305-308.
2. Ances BM, Letendre SL, Alexander T, Ellis RJ. Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int Rev Psychiatry. 2008;20(1):89-93.
3. AIDS Epidemic Update 2009. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO); 2009.
4. Quinn TC, Glasser D, Cannon RO, et al. Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med. 1988;318(4):197-203.
5. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988; 319(24):1573-1578.
6. Moore RD, Keruly J, Richman DD, Creagh-Kirk T, Chaisson RE. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group. AIDS. 1992;6(7):671-677.
7. Food and Drug Administration, US Department of Health and Human Services. HIV/AIDS historical timeline 1981-1990. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm151074.htm. Accessed October 25, 2010.
8. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11(14):1731-1738.
9. Powderly WG. Sorting through confusing messages: the art of HAART. J Acquir Immune Defic Syndr. 2002;31 Suppl 1:S3-S9; discussion S24-S25.
10. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ; National HIV Surveillance Committee. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17(10):1539-1545.
11. Gonzalez R, Cherner M. Co-factors in HIV neurobehavioural disturbances: substance abuse, hepatitis C and aging. Int Rev Psychiatry. 2008;20(1):49-60.
12. Heaton RK, Clifford DB, Franklin DR Jr, et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23): 2087-2096.
13. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243-1250.
14. Heaton RK, Grant I, Butters N, et al. The HNRC 500 - neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1(3):231-251.
15. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry. 2008;20(1):33-47.
16. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517-524.
17. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41(6):778-785.
18. Bottiggi KA, Chang JJ, Schmitt FA, et al. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci. 2007;260(1-2):11-15.
19. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18): 1789-1799.
20. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry. 2008;20(1):25-31.
21. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8(2):136-142.
22. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV dementia and related cognitive disorders. Neurology. 1996;47(5):1247-1253.
23. Marder K, Albert SM, McDermott MP, et al. Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology. 2003;60(9):1467-1473.
24. Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010;75(13):1150-1158.
25. McArthur JC, Sacktor N, Selnes O. Human immunodeficiency virusassociated dementia. Semin Neurol. 1999;19(2):129-150.
26. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157(1-2):3-10.
27. Navia BA, Price RW. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol. 1987;44(1): 65-69.
28. Gray F, Geny C, Lionnet F, et al. Neuropathologic study of 135 adult cases of acquired immunodeficiency syndrome (AIDS). Ann Pathol. 1991;11(4):236-247.
29. Bouwman FH, Skolasky RL, Hes D, et al. Variable progression of HIV-associated dementia. Neurology. 1998;50(6):1814-1820.
30. Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS. Neuropsychological Assessment. 4th ed. New York: Oxford University Press; 2004.
31. McArthur JC, Cohen BA, Selnes OA, et al. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1-infected individuals: results from the multicenter AIDS Cohort Study. Ann Neurol. 1989;26(5):601-611.
32. McArthur JC, Selnes O. Human immunodeficiency virus-associated dementia. In: Berger JR, Levy RM, editors. AIDS and the Nervous System. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1997: 527-567.
33. Butters N, Grant I, Haxby J, et al. Assessment of AIDS-related cognitive changes: recommendations of the NIMH workshop on neuropsychological assessment approaches. J Clin Exp Neuropsychol. 1990;12(6): 963-978.
34. Heaton RK, Miller SW, Taylor MJ, Grant I. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Lutz, FL: Psychological Assessment Resources; 2004.
35. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press; 1993.
36. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(3):273-278.
37. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
38. Lojek E, Bornstein RA. The stability of neurocognitive patterns in HIV infected men: classification considerations. J Clin Exp Neuropsychol. 2005;27(6):665-682.
39. Dawes S, Suarez P, Casey CY, et al; HNRC Group. Variable patterns of neuropsychological performance in HIV-1 infection. J Clin Exp Neuropsychol. 2008;30(6):613-626.
40. Delis DC, Peavy G, Heaton RK, et al; HNRC Group. Do patients with HIV-associated minor cognitive/motor disorder exhibit a "subcortical" memory profile? Evidence using the California verbal learning test. Assessment. 1995;2(2):151-165.
41. Carey CL, Woods SP, Rippeth JD, Heaton RK, Grant I; HIV Neurobehavioral Research Center (HNRC) Group. Prospective memory in HIV-1 infection. J Clin Exp Neuropsychol. 2006;28(4):536-548.
42. Martin EM, Nixon H, Pitrak DL, et al. Characteristics of prospective memory deficits in HIV-seropositive substance-dependent individuals: preliminary observations. J Clin Exp Neuropsychol. 2007;29(5): 496-504.
43. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19(2):152-168.
44. Reger M, Welsh R, Razani J, Martin DJ, Boone KB. A meta-analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc. 2002;8(3):410-424.
45. Bartok JA, Martin EM, Pitrak DL, et al. Working memory deficits in HIV-seropositive drug users. J Int Neuropsychol Soc. 1997;3(5):451-456.
46. Martin EM, Sullivan TS, Reed RA, et al. Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc. 2001;7(1):20-26.
47. Perdices M, Cooper DA. Simple and choice reaction time in patients with human immunodeficiency virus infection. Ann Neurol. 1989; 25(5):460-467.
48. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS. 1999;13(14):1889-1897.
49. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med. 1987;107(6):828-836.
50. Wolters PL, Brouwers P, Civitello L, Moss HA. Receptive and expressive language function of children with symptomatic HIV infection and relationship with disease parameters: a longitudinal 24-month follow-up study. AIDS. 1997;11(9):1135-1144.
51. Levin BE, Berger JR, Didona T, Duncan R. Cognitive function in asymptomatic HIV-1 infection: the effects of age, education, ethnicity, and depression. Neuropsychology. 1992;6(4):303-313.
52. Stern RA, Silva SG, Chaisson N, Evans DL. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol. 1996;53(2): 148-153.
53. Blanchette N, Smith ML, King S, Fernandes-Penney A, Read S. Cognitive development in school-age children with vertically transmitted HIV infection. Dev Neuropsychol. 2002;21(3):223-241.
54. Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry. 2004;161(2):249-254.
55. Iudicello JE, Woods SP, Parsons TD, Moran LM, Carey CL, Grant I. Verbal fluency in HIV infection: a meta-analytic review. J Int Neuropsychol Soc. 2007;13(1):183-189.
56. Woods SP, Morgan EE, Dawson M, Cobb Scott J, Grant I; HIV Neurobehavioral Research Center (HNRC) Group. Action (verb) fluency predicts dependence in instrumental activities of daily living in persons infected with HIV-1. J Clin Exp Neuropsychol. 2006;28(6): 1030-1042.
57. Cysique LA, Maruff P, Brew BJ. The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: a meta-analysis. J Int Neuropsychol Soc. 2006;12(3):368-382.
58. Hardy DJ, Hinkin CH. Reaction time performance in adults with HIV/AIDS. J Clin Exp Neuropsychol. 2002;24(7):912-929.
59. Sacktor NC, Skolasky RL, Lyles RH, Esposito D, Selnes OA, McArthur JC. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol. 2000;6(1):84-88.
60. Foley J, Ettenhofer M, Wright M, Hinkin CH. Emerging issues in the neuropsychology of HIV infection. Curr HIV/AIDS Rep. 2008;5(4): 204-211.
61. Centers for Disease Control and Prevention. HIV prevalence estimates - United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(39): 1073-1076.
62. Van Gorp WG, Miller EN, Marcotte TD, et al. The relationship between age and cognitive impairment in HIV-1 infection: findings from the Multicenter AIDS Cohort Study and a clinical cohort. Neurology. 1994;44(5):929-935.
63. Cherner M, Ellis RJ, Lazzaretto D, et al; HIV Neurobehavioral Research Center Group. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS. 2004;18 Suppl 1:S27-S34.
64. Valcour VG, Shikuma CM, Watters MR, Sacktor NC. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS. 2004;18 Suppl 1:S79-S86.
65. Van Gorp WG, Mitrushina M, Cummings JL, Satz P, Modesitt J. Normal aging and the subcortical encephalopathy of AIDS: a neuropsychological comparison. Neuropsychiatry Neuropsychol Behav Neurol. 1989;2(1):5-20.
66. Foley J, Ettenhofer M, Wright MJ, et al. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol. 2010;24(2):265-285.
67. Wright EJ, Grund B, Robertson K, et al; INSIGHT SMART Study Group. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010; 75(10):864-873.
68. Bergersen BM. Cardiovascular risk in patients with HIV infection: impact of antiretroviral therapy. Drugs. 2006;66(15):1971-1987.
69. Friis-Møller N, Sabin CA, Weber R, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
70. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831-837.
71. Van Gorp WG, Lamb DG, Schmitt FA. Methodologic issues in neuropsychological research with HIV-spectrum disease. Arch Clin Neuropsychol. 1993;8(1):17-33.
72. Centers for Disease Control and Prevention. Coinfection with HIV and hepatitis C virus. 2005. Available from: http://www.cdc.gov/hiv/resources/factsheets/PDF/coinfection.pdf. Accessed September 27, 2010.
73. Paul R, Letendre S, Dearborn J. Impact of hepatitis C coinfection on cognitive outcomes in HIV-infected individuals. Curr Hepatitis Rep. 2007;6(4):145-152.
74. Perry W, Carlson MD, Barakat F, et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS. 2005;19 Suppl 3:S79-S84.
75. Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr. 2002; 31 Suppl 2:S62-S69.
76. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR. Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol. 2001;7(1):66-71.
77. Nath A, Anderson C, Jones M, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol. 2000;14(3):222-227.
78. Bell JE, Brettle RP, Chiswick A, Simmonds P. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain. 1998;121(Pt 11): 2043-2052.
79. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R. Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol. 1991;82(1):39-44.
80. Atkinson JH Jr, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry. 1988;45(9):859-864.
81. Dubé B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci. 2005; 30(4):237-246.
82. Ickovics JR, Hamburger ME, Vlahov D, et al; HIV Epidemiology Research Study Group. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285(11): 1466-1474.
83. Gibbie T, Mijch A, Ellen S, et al. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med. 2006;7(2):112-121.
84. Farinpour R, Miller EN, Satz P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol. 2003;25(5):654-670.
85. Adler NE, Boyce T, Chesney MA, et al. Socioeconomic status and health. The challenge of the gradient. Am Psychol. 1994;49(1):15-24.
86. Smedley BD, Stith AY, Nelson AR, editors. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington (DC): The National Academies Press; 2003.
87. Fox JW. Mothers' influence on their adolescents' tendency to seek medical care. J Adolesc Health. 1991;12(2):116-123.
88. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8(3):448-460.
89. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10): 2015-2028.
90. Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry. 2008;20(1):73-88.
91. Brew BJ. Markers of AIDS dementia complex: the role of cerebrospinal fluid assays. AIDS. 2001;15(14):1883-1884.
92. Avison MJ, Nath A, Berger JR. Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? Trends Neurosci. 2002;25(9):468-473.
93. Aylward EH, Brettschneider PD, McArthur JC, et al. Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am J Psychiatry. 1995;152(7):987-994.
94. Dal Pan GJ, McArthur JH, Aylward E, et al. Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology. 1992;42(11):2125-2130.
95. Stout JC, Ellis RJ, Jernigan TL, et al. Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. Arch Neurol. 1998;55(2):161-168.
96. Kieburtz KD, Ketonen L, Zettelmaier AE, Kido D, Caine ED, Simon JH. Magnetic resonance imaging findings in HIV cognitive impairment. Arch Neurol. 1990;47(6):643-645.
97. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Greenberg RN, Berger JR. Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol. 2004;157(1-2):140-146.
98. Roc AC, Ances BM, Chawla S, et al. Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Arch Neurol. 2007;64(9):1249-1257.
99. Mohamed MA, Lentz MR, Lee V, et al. Factor analysis of proton MR spectroscopic imaging data in HIV infection: metabolite-derived factors help identify infection and dementia. Radiology. 2010;254(2): 577-586.
100. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Washington, DC: US Department of Health and Human Services; December 1, 2009.
101. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2011.
102. Letendre S, Marquie-Beck J, Capparelli E, et al; CHARTER Group. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-70.
103. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR 3rd; International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS. 2009;23(14):1893-1901.
104. Letendre SL, McCutchan JA, Childers ME, et al; HNRC Group. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56(3):416-423.
105. Liner J, Meeker RB, Robertson K. CNS toxicity of antiretroviral drugs. 17th Conference on Retroviruses and Opportunistic Infections; 2010 Feb 16-19; San Francisco, CA, USA.
106. Winston A, Duncombe C, Li PC, et al; Altair Study Group. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50(6):920-929.
107. Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol. 2007;27(1):86-92.
108. Schifitto G, Navia BA, Yiannoutsos CT, et al; Adult AIDS Clinical Trial Group (ACTG) 301; 700 Teams; HIV MRS Consortium. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21(14):1877-1886.